TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…
Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating individuals…
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence…
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended…
HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for…
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a…
Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed…
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot…
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1…